Serum Interleukin 9 Levels Predict Disease Severity and the Clinical Efficacy of Infliximab in Patients with Crohn's Disease

Ting Feng, Baili Chen, Li Li, Shanshan Huang, Shomron Ben-Horin, Yun Qiu, Rui Feng, Manying Li, Ren Mao, Yao He, Zhirong Zeng, Shenghong Zhang*, Minhu Chen

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Abstract

Background: Interleukin (IL)-9 drives gut inflammation, but its role in Crohn's disease (CD) is unclear. We aimed to analyze correlations between serum IL-9 levels and disease severity and to evaluate their predictive value in relation to the clinical efficacy of infliximab (IFX) in patients with CD. Methods: Between January 2013 and December 2015, 100 consecutive patients with active CD and 50 age- and sex-matched control individuals were recruited from a tertiary center. Their serum IL-9 levels were measured using an enzyme-linked immunosorbent assay. Correlations between the serum IL-9 levels and disease severity were examined. The serum IL-9 level was explored as a predictor of clinical remission and mucosal healing at week 30 in 50 patients for whom IFX therapy was administered. Results: The serum IL-9 levels were significantly higher in the patients with active CD (22.0 pg/mL) than in the control individuals (6.3 pg/mL) (P < 0.001); they differed according to disease severity (moderate-to-severe CD: 29.1 pg/mL versus mild CD: 12.9 pg/mL) (P < 0.001), and they correlated well with the clinical activity of CD. IFX lowered the serum IL-9 level in patients who achieved efficacy at week 30. The areas under the curves for the IL-9 levels at weeks 14 and 30 that could predict clinical remission and mucosal healing at week 30 were 0.803 and 0.752 and 0.746 and 0.781, respectively. Conclusions: Serum IL-9 levels correlate with disease severity and the clinical efficacy of IFX in patients with CD, and IL-9 may be a promising novel biomarker for CD monitoring.

Original languageEnglish
Pages (from-to)1817-1824
Number of pages8
JournalInflammatory Bowel Diseases
Volume23
Issue number10
DOIs
StatePublished - 1 Oct 2017
Externally publishedYes

Funding

FundersFunder number
Fundamental Research Fund at Sun Yat-sen University15ykpy12
National Natural Science Foundation of China81630018, 81670498, 81470821
Guangdong Science and Technology Department2014A020212128, 2016A020214006
Pearl River S and T Nova Program of Guangzhou201610010126
Tip-top Scientific and Technical Innovative Youth Talents of Guangdong Special Support Program

    Keywords

    • Crohn's disease
    • clinical efficacy
    • infliximab
    • interleukin 9

    Fingerprint

    Dive into the research topics of 'Serum Interleukin 9 Levels Predict Disease Severity and the Clinical Efficacy of Infliximab in Patients with Crohn's Disease'. Together they form a unique fingerprint.

    Cite this